Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch l4.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma

Authors

James Murray, University Of Alabama At Birmingham, USA
Eugenie Kleinerman, University Of Alabama At Birmingham, USA
Shu-Fang Jia, University Of Alabama At Birmingham, USA
Michael Rosenblum, University Of Alabama At Birmingham, USA
Omar Eton, University Of Alabama At Birmingham, USA
Antonio Buzaid, University Of Alabama At Birmingham, USA
Sewa Legha, University Of Alabama At Birmingham, USA
Merrick Ross, University Of Alabama At Birmingham, USA
Lora Thompson, University Of Alabama At Birmingham, USA
Mansoor Saleh, Aga Khan UniversityFollow

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

We performed a phase Ia/Ib trial of chimeric anti-GD2 monoclonal antibody 14.18 (ch14.18) in combination with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to determine the maximum tolerated dose as well as immunologic and biologic responses to the regimen. Sixteen patients with metastatic malignant melanoma received escalating doses of ch14.18 (15-60 mg/m2) administered intravenously for 4 h on day 1. Twenty-four hours later, subcutaneous injections of rhGM-CSF were administered daily for a total of 14 days. Significant side effects were related to ch14.18 infusion and consisted of moderate to severe abdominal and/or extremity pain, blood pressure changes, headache, nausea, diarrhea, peripheral nerve dysesthesias, myalgias, and weakness. Dose-limiting toxicity was observed at 60 mg/m2 and consisted of severe hypertension, hypotension, and atrial fibrillation in one patient each, respectively. Significant increases in white blood cell count, granulocyte count, eosinophil count, and monocyte count occurred after rhGM-CSF treatment. Significant enhancement of in vitro and in vivo monocyte and neutrophil tumoricidal activity and antibody-dependent cellular cytotoxicity along with significant elevations in C-reactive protein and neopterin were observed. Despite these immunological and biological changes, no antitumor activity was seen. In short, the combination of ch14.18 and rhGM-CSF resulted in toxicity similar to that observed with ch14.18 alone without improvement in tumor response.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Journal of Immunotherapy

DOI

https://doi.org/10.1097/00002371-199605000-00005

Recommended Citation

Murray, J., Kleinerman, E., Jia, S., Rosenblum, M., Eton, O., Buzaid, A., Legha, S., Ross, M., Thompson, L., Saleh, M. (1996). Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch l4.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. Journal of Immunotherapy, 19(3), 206-217.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/118